Cargando…

JAK inhibitors for refractory lymphoma

Detalles Bibliográficos
Autor principal:	Kimura, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152482/ https://www.ncbi.nlm.nih.gov/pubmed/30250636 http://dx.doi.org/10.18632/oncotarget.26054

Ejemplares similares

T cells JAK up integrin activity
por: Short, Ben
Publicado: (2013)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
por: Van Den Neste, Eric, et al.
Publicado: (2018)

Refractory granuloma faciale successfully treated with adjunct topical JAK inhibitor
por: Chen, Ailynna, et al.
Publicado: (2023)

JAK inhibitor, a new player for treatment-refractory microscopic colitis
por: Druez, Anne, et al.
Publicado: (2023)

Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib
por: Yang, Qiao, et al.
Publicado: (2018)

c-Myc steers translation in lymphoma
por: Cargnello, Marie, et al.
Publicado: (2019)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2011)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2014)

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series
por: Xu, Qingqing, et al.
Publicado: (2023)

CD81 as target for B cell lymphomas
por: Küppers, Ralf
Publicado: (2019)

Developing BET-ter treatments for cutaneous T-cell lymphoma
por: Wong, Henry K.
Publicado: (2019)

Harnessing the synergistic potential of biologically targeted therapies in cutaneous T-cell lymphoma
por: Patrone, Christina Chung, et al.
Publicado: (2019)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Gli inhibitor pricked by Hedgehog
por: Short, Ben
Publicado: (2010)

IRAK4 inhibition to shut down TLR signaling in autoimmunity and MyD88-dependent lymphomas
por: Küppers, Ralf
Publicado: (2015)

Chk-mate on resistance to kinase inhibitors
por: Shapiro, Paul
Publicado: (2018)

miR-155 meets the JAK/STAT pathway
por: Persson, Jenny Liao
Publicado: (2013)

A Hedgehog inhibitor gets around
por: Leslie, Mitch
Publicado: (2015)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients
por: Shahriari, Neda, et al.
Publicado: (2023)

JAK inhibitors and COVID-19
por: Levy, Gabriel, et al.
Publicado: (2022)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

JAK1 Selective inhibitors
por: Edwards, Christopher
Publicado: (2021)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

Autophagy inhibitors deliver a knock-out blow
por: Robinson, Richard
Publicado: (2008)

Development of proteasome inhibitors as research tools and cancer drugs
por: Goldberg, Alfred L.
Publicado: (2012)

Rho-Associated Kinase Inhibitors: Potential Future Treatments for Glaucoma
por: Daneshvar, Ramin, et al.
Publicado: (2014)

Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
por: Evens, Andrew M., et al.
Publicado: (2022)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

ROCK Inhibitors can Enhance the Adhesion of Cultured Corneal Endothelial Cells
por: Feizi, Sepehr
Publicado: (2012)

MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma
por: Ramis-Zaldivar, Joan Enric, et al.
Publicado: (2021)

An HTS FP assay able to selectively identify STAT3-DBD inhibitors
por: Meneghetti, Fiorella, et al.
Publicado: (2018)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Selective inhibitors of nuclear export: potential therapeutics for AR variant-expressing prostate cancer
por: Antonarakis, Emmanuel S.
Publicado: (2018)

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer
por: Nucera, Carmelo
Publicado: (2019)

Old drug, new trick: proton pump inhibitors find new purpose in cancer care
por: Ridge, Natalie A., et al.
Publicado: (2021)

Efficacy of JAK inhibitors in Crohn’s Disease
por: Rogler, Gerhard
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oslof1svshheqhnjncsb2rj5va